Pharmacokinetics and pharmacodynamics of subcutaneous injection and intravenous infusion of recombinant human interleukin-12 and recombinant human interleukin-12 combined with hepatitis B surface antigen in cynomolgus monkeys

Pharmacology

Volumn 85, Issue 6, 2010, Pages 319-327

  Li, Rubing ^a   Deng, Fengjun ^a   Fu, Yonghang ^b   Zhang, Yijun ^c   Wan, Huayin ^c   Zhou, Dan ^a   Gu, Jingliang ^d   Xu, Jiangping ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b The 458th Hospital of PLA   (China)

^c Kaitai Biotechnology Co Ltd   (China)

^d JOINN Laboratories   (China)

Author keywords

Cynomolgus monkeys; Hepatitis B surface antigen; Pharmacodynamics; Pharmacokinetics; Recombinant human interleukin 12

Indexed keywords

GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; RECOMBINANT INTERLEUKIN 12; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; RECOMBINANT PROTEIN;

ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CELLULAR IMMUNITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; FEMALE; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MONKEY; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BLOOD; HUMAN; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MACACA FASCICULARIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-12; MACACA FASCICULARIS; MALE; RECOMBINANT PROTEINS;

EID: 77952847552     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000302725     Document Type: Article

References (28)

1. Bramson J, Hitt M, Gallichan WS, Rosenthal KL, Gauldie J, Graham FL: Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum Gene Ther 1996; 7: 333-342.
2. Ma X, Trinchieri G: Regulation of interleukin-12 production in antigen-presenting cells. Adv Immunol 2001; 79: 55-92.
3. Robson NC, Beacock-Sharp H, Donachie AM, Mowat AM: The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes. Immunology 2003; 110: 95-104.
4. Cooper D, Pride MW, Guo M, Cutler M, Mester JC, Nasar F: Interleukin-12 redirects murine immune responses to soluble or aluminum phosphate adsorbed HSV-2 glycoprotein D towards Th1 and CD4+ CTL responses. Vaccine 2004; 23: 236-246.
5. Gupta S, Boppana R, Misha GC, Saha B, Mitra D: Interleukin-12 is necessary for the priming of CD4+ T cells required during the elicitation of HIV-1 gp120-specific cytotoxic T-lymphocyte function. Immunology 2008; 124: 553-561.
6. Tsai YS, Shiau AL, Chen YF, Tsai HT, Lee HL, Tzai TS, Wu CL: Enhancement of antitumor immune response by targeted interleukin-12 electrogene transfer though anti- HER2 single-chain antibody in a murine bladder tumor model. Vaccine 2009; 27: 5383-5392.
7. Cavanaugh VJ, Guidotti LG, Chisari FV: Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 1997; 71: 3236-3243.
8. Cho SW, Cheong JY, Ju YS, Oh do H, Suh YJ, Lee KW: Human leukocyte antigen class II association with spontaneous recovery from hepatitis B virus infection in Koreans: analysis at the haplotype level. J Korean Med Sci 2008; 23: 838-844.
9. Frelin L, Wahlström T, Tucker AE, Jones J, Hughes J, Lee BO, Billaud JN, Peters C, Whitacre D, Peterson D, Milich DR: A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection. J Virol 2009; 83: 1379-1392.
10. Tang TJ, Kwekkeboom J, Laman JD, Niesters HG, Zondervan PE, de Man RA, Schalm SW, Janssen HL: The role of intrahepatic immune effector cells in inflammatory liver injury and viral control during chronic hepatitis B infection. J Viral Hepat 2003; 10: 159-167.
11. Rigopoulou EI, Suri D, Chokshi S, Mullerova I, Rice S, Tedder RS, Williams R, Naoumov NV: Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology 2005; 42: 1028-1036.
12. Nadeau RR, Ostrowski C, Ni-Wu G, Liberato DJ: Pharmacokinetics and pharmacodynamics of recombinant human interleukin- in male rhesus monkeys. J Pharmacol Exp Ther 1995; 274: 78-83.
13. Carreno V, Zeuzem S, Hopf U, Marcellin P, Cooksley WG, Fevery J, Diago M, Reddy R, Peters M, Rittweger K, Rakhit A, Pardo M: A phase I/II study of recombinant human interleukin- in patients with chronic hepatitis B. J Hepatol 2000; 32: 317-324.
14. Zeuzem S, Carreno V: Interleukin-12 in the treatment of chronic hepatitis B and C. Antiviral Res 2001; 52: 181-188.
15. Cohen J: IL-12 deaths: explanation and a puzzle. Science 1995; 270: 908.
16. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon- gamma production. Blood 1997; 90: 2541-2548.
17. Xiong SQ, Lin BL, Gao X, Tang H, Wu CY: IL-12 promotes HBV-specific central memory CD8+ T cell responses by PBMCs from chronic hepatitis B virus carriers. Int Immunopharmacol 2007; 7: 578-587.
18. Guha C, Mohan S, Roy-Chowdhury N, Roy- Chowdhury J: Cell culture and animal models of viral hepatitis. Part I: Hepatitis B. Lab Anim (NY) 2004; 33: 37-46.
19. Wang SS, Su JJ, Feng BF, Li Y, Zhang T, Qin LL, Huang GY, Gao JE, Ge XM, Li HM: Serial pathologic changes in livers of tree shrews and Macaca assamensis infected with human hepatitis B virus (in Chinese). Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2003; 17: 244-246.
20. Jia RS, Zhang GW: Research and application of hepatitis B virus animal models. J Clin Rehabil Tissue Eng Res 2008; 12: 7368-7373.
21. Ikegami K, Tagawa K, Narisawa S, Osawa T: Suitability of the cynomolgus monkey as an animal model for drug absorption studies of oral dosage forms from the viewpoint of gastrointestinal physiology. Biol Pharm Bull 2003; 26: 1442-1447.
22. Uno Y, Sakuraba H, Uehara S, Kumano T, Matsuno K, Nakamura C, Kito G, Kamataki T, Nagata R: A null allele impairs function of CYP2C76 gene in cynomolgus monkeys: a possible genetic tool for generation of a better animal model in drug metabolism. Drug Metab Dispos 2009; 37: 14-17.
23. Suzuki Y, Tanaka K, Negishi D, Shimizu M, Yoshida Y, Hashimoto T, Yamazaki H: Pharmacokinetic investigation of increased efficacy against malignant gliomas of carboplatin combined with hyperbaric oxygenation. Neurol Med Chir (Tokyo) 2009; 49: 193-197.
24. Chen Z, Cheng Y, Xu Y, Liao J, Zhang X, Hu Y, Zhang Q, Wang J, Zhang Z, Shen F, Yuan Z: Expression profiles and function of Tolllike receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol 2008; 128: 400-408.
25. Lenzi R, Rosenblum M, Verschaegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL, Freedman RS: Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 2002; 8: 3686-3695.
26. Trudeau C, Cotreau MM, Stonis L, Dykstra KH, Oestreicher JL, Strahs A, Dorner AJ, Van Cleave VH, Trepicchio WL, Schwertschlag US: A single administration of recombinant human interleukin-12 is associated with increased expression levels of interferon-gamma and signal transducer and activator of transcription in healthy subjects. J Clin Pharmacol 2005; 45: 649-658.
27. Wang Y, Chaudhi G, Jackson RJ, Karupiah G: IL-12p40 and IL-18 play pivotal roles in orchestrating the cell-mediated immune response to a poxvirus infection. J Immunol 2009; 183: 3324-3331.
28. Van Herpen CM, Huijbens R, Looman M, De Vries J, Marres H, Van De Ven J, Hermsen R, Adema GJ, De Mulder PH: Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells. Clin Cancer Res 2003; 9: 2950-2956.